TIDMGEN
Company Announcement
COPENHAGEN, Denmark; February 28, 2023 --
https://www.globenewswire.com/Tracker?data=NqkGwBzG2ZkeO_WsCN-5zSM1oXA58em0odCeU1cwUYTy7UK8srROM0PuEQ38YN5i2-r9ZLhT8CXnmyWps-FfVA==
Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,359
shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the
existing shareholders of the company or others. The shares are
subscribed in cash at the following price per share of nominally
DKK 1:
2,725 shares at DKK 815.50,
163 shares at DKK 962.00,
804 shares at DKK 1,025.00,
93 shares at DKK 1,032.00,
1,107 shares at DKK 1,050.00,
80 shares at DKK 1,136.00,
525 shares at DKK 1,145.00,
444 shares at DKK 1,147.50,
428 shares at DKK 1,155.00,
591 shares at DKK 1,161.00,
580 shares at DKK 1,210.00,
799 shares at DKK 1,233.00,
3,526 shares at DKK 1,334.50,
8,400 shares at DKK 1,427.00, and
4,094 shares at DKK 1,615.00.
Proceeds to the company are approximately DKK 31.8 million. The
increase corresponds to approximately 0.04% of the company's share
capital.
The new shares are ordinary shares without any special rights
and are freely transferable negotiable instruments. The new shares
give rights to dividends and other rights in relation to the
company as of subscription. The new shares will be listed on Nasdaq
Copenhagen after registration with the Danish Business Authority.
The capital increase is expected to be finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No. 41
of January 13, 2023, it is hereby announced, that the total nominal
value of Genmab A/S' share capital after the capital increase is
DKK 65,985,932 which is made up of 65,985,932 shares of a nominal
value of DKK 1 each, corresponding to 65,985,932 votes.
About Genmab
Genmab is an international biotechnology company with a core
purpose guiding its unstoppable team to strive towards improving
the lives of patients through innovative and differentiated
antibody therapeutics. For more than 20 years, its passionate,
innovative and collaborative team has invented next-generation
antibody technology platforms and leveraged translational research
and data sciences, which has resulted in a proprietary pipeline
including bispecific T-cell engagers, next-generation immune
checkpoint modulators, effector function enhanced antibodies and
antibody-drug conjugates. To help develop and deliver novel
antibody therapies to patients, Genmab has formed 20+ strategic
partnerships with biotechnology and pharmaceutical companies. By
2030, Genmab's vision is to transform the lives of people with
cancer and other serious diseases with Knock-Your-Socks-Off (KYSO)
antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen,
Denmark with locations in Utrecht, the Netherlands, Princeton, New
Jersey, U.S. and Tokyo, Japan. For more information, please visit
https://www.globenewswire.com/Tracker?data=NqkGwBzG2ZkeO_WsCN-5zS574s6ORY9tKuH1yQzWpNGZfkl3LituDo7z9xDjJrp-Q5W6LXedmeC0uMiqnzfyew==
Genmab.com and follow us on
https://www.globenewswire.com/Tracker?data=KwwMHUtInnvYYR-1JHKkdBHFLinyiqChfjdu-ywRcfOpO5GWmq8jARuc_gjTsDjx3UV3eKuiTSHGUF6CvPsg3XvsVg3ZUs7imilW_1M-AtY=
Twitter.com/Genmab.
Contact:
Marisol Peron, Senior Vice President, Global Communications
& Corporate Affairs
T: +1 609 524 0065; E:
https://www.globenewswire.com/Tracker?data=mjf5LsyH34mbVUocYWGsxt8AUCtE1z1UauVTNYMiIwwGd8-IxqL9ZJ9i9GHf0Y97b3Cqv_79-a3IOtuga-YUbA==
mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E:
https://www.globenewswire.com/Tracker?data=l0TNJhvEXwrdB4G78naxQKx77GM7COqEN1Lj7YtGqKYdV_GVb2ofwc5ATLeXox46hVJhzEt_4sXOWKFeOMcFvQ==
acn@genmab.com
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=NYFc9qJeKcWBct3prmB_Rud8uqZ48h9sAU5aCKxJNNzCcg8qfd_OuolPHWOFQegvJbyzfiSah7BK5cMq6UAutA==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=NYFc9qJeKcWBct3prmB_RsPNfD2r8zAtf8ps95bB4daMb1AOWz6-bB0nwFyjj_inhTfm1paNcf70B1JZpvvnYUPFX_4qqGrMKiSuDOrtDpg=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Company Announcement nor
to confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody
in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in
combination with the HexaBody logo(R) ; DuoHexaBody(R) and
HexElect(R) .
Company Announcement no. 12
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
-- 280223_CA12_Warrant Exercise_
https://ml-eu.globenewswire.com/Resource/Download/a24c8521-3de7-4c6e-91da-a6bea89f898f
(END) Dow Jones Newswires
February 28, 2023 14:54 ET (19:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genuit (LSE:GEN)
Historical Stock Chart
From Apr 2023 to Apr 2024